Key result
Pimobendan had similar mechanoenergetic effects to dobutamine in nonfailing dog hearts, but demonstrated a 14 +/- 19% greater contractile economy (p<0.05) and greater coronary vasodilation.
Why the study?
Does pimobendan improve left ventricular contractility and energetics compared to dobutamine in excised, cross-circulated, nonfailing dog hearts?
Does pimobendan improve left ventricular contractility and energetics compared to dobutamine in excised, cross-circulated, nonfailing dog hearts?
p-value: p=<0.05
In a canine model, pimobendan's calcium-sensitizing effect did not reduce the oxygen cost of contractility compared to dobutamine, though it offered slightly greater contractile economy and coronary vasodilation.
No takes yet. Share an insight, caveat, or question.
No immediate clinical implications for inotrope selection; leaves open translation of energetic advantages to failing human hearts.
Hata et al. (1992) studied nonfailing dog hearts. Pimobendan vs. Dobutamine was evaluated on Left ventricular contractility and energetics (VO2, Emax, PVA, and force-time integral) (p=<0.05). Pimobendan had similar mechanoenergetic effects to dobutamine in nonfailing dog hearts, but demonstrated a 14 +/- 19% greater contractile economy (p<0.05) and greater coronary vasodilation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: